Estradiol influences p53 expression in a human endometrial adenocarcinoma heterotransplanted into nude mice

In Vivo

Volumn 10, Issue 1, 1996, Pages 29-32

  Horvath, György ^a   Leser, Gunilla ^a   Delle, Ulla ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Endometrial adenocarcinoma; Estradiol; p53 expression

Indexed keywords

BROXURIDINE; ESTRADIOL; ESTROGEN RECEPTOR; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRAFT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL KINETICS; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HALF LIFE TIME; HUMAN; HUMAN TISSUE; METAPHASE; MOUSE; NONHUMAN; QUANTITATIVE ASSAY; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

EID: 0029890194     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Greene GL, Gillna P, Waterfield M, Baker A, Hort Yand Shine I: Sequence and expression of human estrogen receptor complementary DNA. Science 231: 1145-1154, 1986.
2. Sixkaon EB, Bates S, Mc Manaway ME and Lippman ME: Characterization of estrogen responsive transforming activity in human breast cancer cell lines. Cancer Res 46: 1707-1713, 1986.
3. Levine A J, Momand J, and Finlay CA: The p53 tumour suppressor gene. Nature 351: 453-456, 1991.
4. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
5. Momand J, Zambetti GP, Olson, DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245, 1992.
6. Lane D: p53, guardian of the genome. Nature 358: 15-16, 1992.
7. Perry M E, Levine AJ: Tumor-supressor p53 and the cell cycle. Curr Opin Genet Dev 3: 50-54, 1993.
8. Horvath G, Tropé A, Alm P, Ferno M: Heterotransplantation of human malignant endometrial tumors into nude mice. In Vivo 2: 361-366, 1988.
9. Osaieka R, Houchens D, Goldin A, Johnsson RK: Chemotherapy of human colon cancer xenografts in athymic nude mice. Cancer 40: 2640-2650, 1977.
10. Horvath G, Fernö M, Cameron R, Ranstam J: Estrogen receptor activation in relation to previous estrogen treatment in carcinoma corporis uteri heterotransplanted into nude mice. In Vivo 3: 93-98, 1989.
11. Barkley MS, Lasley BL, Thompson MA, Shackleton CHL: Equol: a contributor to enigmatic immunoassay measurements of estrogen. Steroids 46: 587-608, 1985.
12. Dolheare F, Gratzner H, Pallavicini MG, Gray JW Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc Natl Acad Sci USA 80: 5573-5580, 1985.
13. Wison GD McNally NJ, Dynphy E, Karcher H, Pfranger R: The labelling index of human and mouse tumors assessed by bromodeoxyuridine stating in vitro and in vivo and flow cytometry. Cytometry 6: 641-647, 1985.
14. Begg AD, McNall, NJ, Shrieve DS, Karcher H: A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 6: 620-626, 1985.
15. Steel GD: Growth kinetics of tumours. Oxford, Clareddon Press. 1977.
16. Laemli UK: Cleavage of structural proteins during assembly of the head of bacteriophage T3. Nature 277: 15-16, 1970.
17. Jin L, Song JY, Lloyd EV: Estrogen stimulated both prolactin and growth hormone mRNAs expression in the MtT/F4 transplantable pituitary tumor. Proc Soc Exp Biol Med 192: 225-229, 1989.
18. Kulig E, Landefeld TD, Lloyd RV: The effects of estrogen on prolactin gene methylation in normal and neoplastic rat pituitary tissues. Am J Pathol 140: 207-214, 1992.
19. Ottaviano YL, Issa JP, Pari F F, Smith HS, Baylin SB, Davidson EE: Methylation of the estrogen receptor gene CpG islands marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 54: 2552-2555, 1994.
20. Razin A, Rings AD: DNA methylation and gene function. Science 210: 604-610, 1980.
21. Bird AP: CpG-rich islands and the function of DNA methylation. Nature (London) 321: 209-213, 1986.
22. Li E, Beard C, Jaenisch R: Role for DNA methylation in genomic imprinting. Nature (London) 366: 362-365, 1993.
23. Zhang W, McClain C, Gau J, Gau X, Deisseroth AB: Hyperphosphorylation of p53 induced by okadic acid attenuates its transcriptional activation function. Cancer Res 54: 4448-4453, 1994.
24. Kern SE, Pletenpol J, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein BV: Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (Washington DC) 256: 827-830, 1992.
25. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM: Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54: 2095-2097, 1994.